CDEK
← All drugs Report issue

rapastinel

Small moleculeexperimental

Rapastinel is a novel antidepressant that was under development by Allergan as an adjunctive therapy for the treatment of treatment-resistant depression. It is a centrally active, intravenously administered amidated tetrapeptide that acts as a novel and selective modulator of the NMDA receptor. The drug is a rapid-acting and long-lasting antidepressant as well as robust cognitive enhancer by virtue of its ability to enhance NMDA receptor-mediated signal transduction and synaptic plasticity. — Wikipedia

Clinical trial activity

19 trials · 14 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
16
Phase 3
10
Phase 4
0

Earliest trial started Nov 1, 2009 (NCT01014650)

Timeline

2000s

  1. Jan 1, 2009

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2016

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(N)=O)[C@@H](C)O
Mol. weight
413.48 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • glyx-13
  • glyx-13
  • glyx-13
  • glyx-13 peptide
  • rapastinel
  • rapastinel
  • rapastinel
  • rapastinel
  • rapastinel
  • tppt-amide

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03855865Phase 3Jul 1, 2019Allergan
NCT03814733Phase 1Nov 14, 2018Allergan
NCT03799900Phase 1Nov 1, 2018Allergan
NCT03675776Phase 3Oct 1, 2018Allergan
NCT03668600Phase 3Aug 23, 2018Allergan
NCT03614156Phase 3Aug 7, 2018Allergan
NCT03560518Phase 3Jun 15, 2018Allergan
NCT03352453Phase 2Dec 5, 2017Allergan
NCT03002077Phase 3Feb 3, 2017Allergan
NCT02951988Phase 3Nov 13, 2016Allergan
NCT02943577Phase 3Nov 2, 2016Allergan
NCT02943564Phase 3Nov 1, 2016Allergan
NCT02932943Phase 3Oct 15, 2016Allergan
NCT02192099Phase 2Feb 1, 2015Allergan, Naurex
NCT02267629Phase 2Oct 1, 2014Columbia University, Stanford University
NCT01844726Phase 2May 1, 2013Northwestern University
NCT01684163Phase 2Nov 1, 2012Allergan, Naurex
NCT01234558Phase 2May 1, 2011Artemis Institute for Clinical Research, Claghorn-Lesem Research Clinic, Houston TX, Clinilabs, CNRI-LA, Pico Rivera CA, CRI-WW Lordes Hospital, Willingboro NJ, Lehigh Center for Clinical Research, Lynn Health Science Institute, Naurex, The University of Texas, Dallas
NCT01014650Phase 1Nov 1, 2009Lotus Clinical Research, Naurex
Showing 19 of 19 trials
Page 1 / 1

Organizations

Research & Development (14)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AllerganFor profit151332012
NaurexFor profit4422009
Artemis Institute for Clinical ResearchFor profit1012011
Claghorn-Lesem Research Clinic, Houston TXFor profit1012011
ClinilabsFor profit1012011
CNRI-LA, Pico Rivera CAFor profit1012011
Columbia UniversityAcademic/Hospital1112014
CRI-WW Lordes Hospital, Willingboro NJAcademic/Hospital1012011
Lehigh Center for Clinical ResearchAcademic/Hospital1012011
Lotus Clinical ResearchFor profit1012009
Lynn Health Science InstituteAcademic/Hospital1012011
Northwestern UniversityAcademic/Hospital1112013
Stanford UniversityAcademic/Hospital1012014
The University of Texas, DallasAcademic/Hospital1012011
14 organizations
Page 1 / 1